Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01915823 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 348
- Enrollment target
NCT01915823 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 348 participants.
The verdict
NCT01915823, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 348 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Dymista nasal spray is better and safer than placebo in treating children ages 4 to \<12 years old who have seasonal allergic rhinitis.
Interventions
- DRUG azelastine hydrochloride and fluticasone propionate
- DRUG Dymista vehicle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2013-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01915823
The ClinicalTrials.gov registry entry for NCT01915823 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 348 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Meda Pharmaceuticals, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which azelastine hydrochloride and fluticasone propionate is the first listed.
NCT01915823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01915823 about?
NCT01915823 is a clinical study titled "Safety and Efficacy Trial of Dymista Nasal Spray in Children Ages 4 to 11 With Seasonal Allergic Rhinitis (SAR)". The purpose of this study is to determine if Dymista nasal spray is better and safer than placebo in treating children ages 4 to \<12 years old who have seasonal allergic rhinitis.
What is the current status of trial NCT01915823?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 348 participants. The study started on 2013-07.
What interventions are being tested in trial NCT01915823?
The interventions under investigation include: azelastine hydrochloride and fluticasone propionate (DRUG), Dymista vehicle (DRUG).
Who is sponsoring clinical trial NCT01915823?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.